Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens

Go back to Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens
ING Van Kampen Equity Growth Fund S 2 Class (NASDAQ: VKTX) Delayed: 26.38 --0 (-0%)
Previous Close $26.38    52 Week High $5.17 
Open $26.38    52 Week Low $0.94 
Day High $26.38    P/E N/A 
Day Low $26.38    EPS $0.00 
Volume 3,161